F. Penault Llorca

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

C. Turnbull, J. Daurès, P. Pujol, 2022, Cancers.

Resistance to human epidermal growth factor receptor type 2-targeted therapies.

E. Raymond, J. Spano, D. Azria, 2014, European journal of cancer.

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis.

B. Esterni, P. Rouanet, P. Bonnier, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer.

P. Lamy, S. Romain, L. Ouafik, 2006, The International journal of biological markers.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

C. Haie-meder, P. Arveux, I. Ray-Coquard, 2012, Bulletin du cancer.

Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study.

B. Esterni, D. Hudry, G. Houvenaeghel, 2014, Breast.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

H. Wildiers, J. Bogaerts, J. Yarnold, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.